TEST:

Elecsys Anti-p53 Immunoassay

Conclusions The existence of a TP53 gene mutation in patients' tumor significantly impacted their PFS, suggesting that future clinical trials should include TP53 genotyping at randomization. Baseline quantification of anti-p53 antibodies could also be used to early identify a fraction of patients presenting a TP53 alteration, and identify patients who may benefit less from osimertinib treatment.

When the specificities of the two assays were aligned for all samples, Elecsys demonstrated higher sensitivities for all types of analyzed cancer together, as well as for esophageal, colorectal and breast cancer, respectively. Although positive concordance between the two assay systems was low in terms of specificity, Elecsys had a higher sensitivity than the MESACUP.

"The new s-p53-Abs assay Elecsys anti-p53 was useful in detecting esophageal and colorectal cancers with high specificity. Adding s-p53-Abs to conventional markers significantly improved the overall detection rates."